key: cord-0950594-8pc26cnb authors: Paris, C; Saade, A; Tadié, E; Nguyen Van, R; Turmel, V; Garlantezec, R; Tattevin, P title: Determinants of the willingness to get the third COVID-19 vaccine dose among health care workers date: 2022-05-02 journal: Infect Dis Now DOI: 10.1016/j.idnow.2022.04.007 sha: f16b3e4d22a413213692e40439136fb848f260e3 doc_id: 950594 cord_uid: 8pc26cnb Objective. To characterize the willingness to get the third COVID-19 vaccine dose among health care workers (HCWs). Methods. A cross-sectional study using a self-administered questionnaire proposed on a voluntary basis to all HCWs of a French teaching hospital in October and November 2021. Results. Of 1,655 HCWs who completed the questionnaire, 64.2% were willing to receive the third dose, 20.1% were hesitant, and 15.7% were reluctant. On multivariate analysis, older age (p<0.0001), medical and executive staff, willingness to receive the flu vaccine (OR=5.72 [4.24-7.64]), previous vaccine scheme with ChAdOx1 nCoV-19 (AstraZeneca) (OR=2.13 [1.58-2.87]), and history of COVID-19 with a complete COVID-19 vaccine scheme (OR=2.77 [1.04-7.41]) were independent predictors of HCWs’ willingness to get the third dose. Conclusions. One third of HCWs were hesitant or opposed to a third COVID-19 vaccine dose. Better knowledge of determinants of the willingness to get this third dose may improve communication and vaccine strategy. Health care workers (HCWs) are at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to their exposure to patients and to their household and community exposure [1] . Several vaccines have been developed with high effectiveness [2] [3] [4] . HCWs were among the priority target populations to protect them, their patients, and their relatives, and to avoid HCW absenteeism. In France vaccination of HCWs began in January 2021 on a voluntary basis. Since September 15, 2021, complete vaccination (two doses of vaccine) was made compulsory for all HCWs. Unfortunately, breakthrough infections were reported in fully vaccinated HCWs as early as August 2021, irrespective of the vaccine scheme [5] [6] . More recently, Yamamoto et al. reported COVID-19 breakthrough infections among fully vaccinated HCWs during the fifth wave, dominated by the delta variant [7] . At the same time, reduced vaccine effectiveness was reported as early as 3 months after the second vaccine dose in the general population [8] [9] [10] highlighting the need for a third dose, particularly in HCWs [11] . Several landmark papers confirmed the effectiveness of a third dose in various populations, with a dramatic impact on the COVID-19 incidence [12] , but also on COVID-19 severity [13] and mortality [14] . However, acceptance of this initially unplanned third dose raised concerns in the overall context of vaccine hesitancy worldwide, particularly regarding COVID-19 vaccines [15] [16] [17] [18] . Characteristics and determinants of the general population's and HCWs' willingness to get the third COVID-19 vaccine dose has not attracted much attention to date. We performed a cross sectional study to characterize the intention of HCWs towards this third vaccine dose, as well as their determinants. We first conducted a univariate analysis to describe the associations between the willingness to get the third COVID-19 vaccine dose (categorized as pro / hesitant / con) and HCW characteristics, flu vaccination status, COVID-19 history, and previous scheme of COVID-19 vaccination. All multivariate models were a priori systematically adjusted for age, gender, and occupation and then all variables associated with a p value <0.20 were computed by a stepwise multivariate analysis based on a logistic regression model, where the primary outcome was modelled in a binary approach: i) pro; ii) hesitant or con. Results are presented as odds ratio (OR) with their 95% confidence intervals. A p value below 0.05 was considered significant. Statistical analyses were performed using the SAS® package, v9.4. Overall, 1,713 HCWs completed the questionnaire (participation rate: 21.5%). We (Table 1 ). In univariate analysis, older age (p<0.0001) and occupation ─ namely health executives and medical staff ─ (p<0.0001) were associated with the willingness to receive the third dose. Previous or current regular flu vaccination ( We observed that the willingness to receive a third dose of COVID-19 vaccine in HCWs was associated with older age, flu vaccination status, and specific occupations (i.e. health executives and medical staff as compared to non-medical HCWs). Interestingly, on multivariate analysis we identified unexpected independent predictors of willingness to get the third dose: i) history of COVID-19 in HCWs with adequate vaccination scheme, and ii) previous vaccine scheme with a least one dose of ChAdOx1 nCoV-19. The association between older age and willingness to receive a COVID-19 vaccine was identified in most studies on COVID-19 vaccine hesitancy, for the first dose and in the general population as well [15] [16] . This probably reflects individual motivation, as age is the most powerful predictor of poor outcome after COVID-19 especially in a population of workers with a relatively low frequency of other risk factors. Hence, the benefit/risk ratio of COVID-19 vaccine appears particularly obvious in older individuals. The association of the flu vaccination status and the willingness to receive the COVID-19 vaccine is also quite intuitive, as both are associated with similar characteristics, including trust in institutional vaccine recommendations and awareness that HCWs are at high risk of transmitting these viruses to patients and relatives [16] . The most surprising findings of our study are as follows. Firstly, previous administration of the ChAdOx1 nCoV-19 vaccine was independently associated with the willingness to get the third COVID-19 vaccine dose. This may be due to convincing data that the effectiveness of the Hence, HCWs previously vaccinated with the ChAdOx1 nCoV-19 vaccine seems more likely to ask for a third dose to improve their immune response against the delta variant. Secondly, the heterogeneous association between history of COVID-19 and willingness to receive the third vaccine dose is less clear: previous COVID-19 infection in HCWs was associated with a higher or with a lower willingness to get the third dose depending on their COVID-19 vaccination scheme. We may hypothesize that past medical history of COVID-19 would reinforce the willingness to receive the third dose in order to avoid the previously experienced COVID-19 symptoms and to reinforce protection. However, the reason it would only apply to HCWs with a complete previous vaccine scheme remains unclear. Our data may suggest that HCWs with a COVID-19 history and a single dose of COVID-19 vaccine in a context of complete mandatory scheme represent a population less prone to the vaccine. Our study has several limitations. First, as it was a monocentric study conducted over a short period of time, its findings may not be generalizable to other settings or other periods of the COVID-19 pandemics. These limitations are particularly relevant given the rapid evolution of the epidemiology, scientific knowledge, and HCWs' feelings about the COVID-19 pandemic and the optimal way to manage it [16] . Second, the recruitment of subjects on a voluntary basis implies that representability may not be guaranteed even if the general characteristics of respondents did not differ from those of the whole population (data not shown). Third, we only collected declarative data, and no control of answer accuracy was performed. However, this study has several strengths such as its large sample size (1, 655 questionnaires evaluated), the anonymous collection of data, and the focus on an important issue which has thus far not been investigated (to our knowledge). Indeed, as it became obvious that a third dose of COVID-19 vaccine seemed necessary to boost the protection of the population [11] [12] [13] , including HCWs, better knowledge of determinants of the willingness to get this third dose may improve communication and vaccine strategy, particularly regarding HCWs as it is a key population in the fight against COVID-19. In conclusion, we found that most eligible HCWs (64%) were willing to receive the third COVID-19 vaccine dose, while 20% were hesitant, and 16% were opposed to it. Older age, specific occupation categories, influenza vaccine status, and having received the ChAdOx1 nCoV-19 vaccine were associated with willingness to receive the third dose. Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lan Risk factors for SARS-CoV-2 infection among health care workers Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Vaccine Breakthrough Infections with SARS-CoV-2 Variants Covid-19 Breakthrough Infections in Vaccinated Health Care Workers COVID-19 breakthrough infection and postvaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study Waning Immunity after the BNT162b2 Vaccine in Israel Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study Time course of antibody concentrations against the spike protein of SARS-CoV-2 among healthy hospital workers up to 200 days after their first COVID-19 vaccination Protection against Covid-19 by BNT162b2 Booster across Age Groups Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study BNT162b2 Vaccine Booster and Mortality Due to Covid-19 Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review COVID-19 vaccine hesitancy among healthcare workers Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada value, logistic model, univariate analysis 2 : subjects with an incomplete vaccine scheme (no information on some doses) and COVID-19 history